文献速递高血压血脂与心血管预防

1999-2023年美国高血压成人心代谢风险因素患病率、治疗与控制趋势

Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
PubMed 文献 · J Am Coll Cardiol · 2025-11-26

该研究基于NHANES 1999-2023年21,822名高血压成人,评估糖尿病、高脂血症、肥胖、吸烟及高危饮酒的年龄标化患病率及治疗控制趋势。结果显示心代谢风险负担整体增加,并发糖尿病和高脂血症者超过1/5,但三者均控制者仅约1/4且十余年未改善。

要点

  • 高血压成人中糖尿病患病率从1999-2000年的17.2%升至2021-2023年的27.8%。
  • 高血压合并糖尿病、高脂血症者三种疾病均控制率2021-2023年仅26.3%,十余年无改善。
  • 高血压成人中高脂血症患病率仍高达73.1%,肥胖和高危饮酒患病率随时间增加。

核心结论

  • 美国高血压成人心代谢风险因素负担整体增加,并发糖尿病和高脂血症者超过1/5。
  • 高血压、糖尿病和高脂血症三者均控制的比例仅约四分之一,且十余年未改善。

研究设计与样本

  • 基于美国国家健康与营养调查(NHANES)1999至2023年数据,纳入21,822名高血压成人。
  • 评估糖尿病、高脂血症、肥胖、吸烟和高危饮酒的年龄标化患病率,以及高血压、糖尿病和高脂血症的年龄标化治疗率和控制率趋势。

主要发现

  • 高血压成人中糖尿病患病率从1999-2000年的17.2%(95%CI 14.6%-20.2%)升至2021-2023年的27.8%(95%CI 25.2%-30.7%)。
  • 高血压合并糖尿病患者中,两者均治疗的比例升至2009-2010年后平台,2021-2023年为71.6%(95%CI 67.5%-75.4%);两者均控制的比例2021-2023年为31.2%(95%CI 26.5%-36.3%)。
  • 高血压成人中高脂血症患病率下降但2021-2023年仍达73.1%(95%CI 70.6%-75.4%);高血压合并高脂血症者两者均治疗和控制的比率仅增至约2007年,2021-2023年分别为50.4%(95%CI 47.2%-53.6%)和32.3%(95%CI 29.5%-35.2%)。
  • 高血压成人中并发糖尿病和高脂血症的患病率从1999-2000年的12.5%(95%CI 10.6%-14.7%)几乎翻倍至2021-2023年的21.3%(95%CI 19.0%-23.8%)。
  • 高血压、糖尿病和高脂血症三者均治疗的比例增至2007-2008年后平台,2021-2023年为62.1%(95%CI 56.6%-67.2%);三者均控制的比例趋势相似但2021-2023年仍低至26.3%(95%CI 20.8%-32.6%)。

临床怎么用

  • 对高血压患者应常规筛查并管理糖尿病、高脂血症、肥胖及高危饮酒等心代谢风险因素。
  • 高血压合并糖尿病和/或高脂血症者治疗率虽提高但控制率低,需强化多因素综合管理以改善控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension-related deaths in the United States have sharply increased over the past decade. Understanding factors behind this concerning trend is crucial to guide public health strategies. OBJECTIVES: This study sought to examine changes in prevalence, treatment, and control of cardiometabolic risk factors among U.S. adults with hypertension. METHODS: Using National Health and Nutrition Examination Survey, we identified 21,822 adults with hypertension from 1999 to 2023. Trends in age-adjusted prevalence of diabetes, hyperlipidemia, obesity, smoking, and high-risk drinking, as well as in age-adjusted treatment and control rates for hypertension, diabetes, and hyperlipidemia, were assessed. RESULTS: In adults with hypertension, prevalence of diabetes increased from 17.2% (95% CI: 14.6%-20.2%) in 1999-2000 to 27.8% (95% CI: 25.2%-30.7%) in 2021-2023. Among patients with hypertension and diabetes, the proportion receiving treatment for both conditions rose until 2009-2010 but subsequently plateaued (71.6% in 2021-2023; 95% CI: 67.5%-75.4%). A similar trend was observed for the proportion achieving control of both conditions, which remained at 31.2% in 2021-2023 (95% CI: 26.5%-36.3%). Prevalence of hyperlipidemia decreased in adults with hypertension but was still high at 73.1% (95% CI: 70.6%-75.4%) in 2021-2023. Among patients with hypertension and hyperlipidemia, treatment and control rates for both conditions increased only until around 2007; the respective rates were 50.4% (95% CI: 47.2%-53.6%) and 32.3% (95% CI: 29.5%-35.2%) in 2021-2023. Prevalence of concurrent diabetes and hyperlipidemia in adults with hypertension nearly doubled from 12.5% (95% CI: 10.6%-14.7%) in 1999-2000 to 21.3% (95% CI: 19.0%-23.8%) in 2021-2023. Among patients with hypertension, diabetes, and hyperlipidemia, the treatment rate for all 3 conditions increased until 2007-2008 and plateaued afterward (62.1% in 2021-2023; 95% CI: 56.6%-67.2%). The control rate for all 3 conditions followed a similar trend but remained low at 26.3% (95% CI: 20.8%-32.6%) in 2021-2023. Prevalence of obesity and high-risk drinking increased over time, whereas prevalence of smoking held steady. CONCLUSIONS: The burden of cardiometabolic risk factors among U.S. adults with hypertension has increased overall, with concurrent diabetes and hyperlipidemia now affecting more than 1 in 5. Only one-quarter of adults with hypertension, diabetes, and hyperlipidemia have all 3 conditions controlled-a proportion that has not improved in more than a decade.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee HH, Crawford EB, Cho SMJ, et al. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. J Am Coll Cardiol. 2025. PMID: 41295934. doi:10.1016/j.jacc.2025.09.1607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。